BJR
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

British Journal of Radiology (2007) 80, 569-573
© 2007 British Institute of Radiology
doi: 10.1259/bjr/95414884

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lohrmann, C
Right arrow Articles by Langer, M
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lohrmann, C
Right arrow Articles by Langer, M

Full paper

Gadoteridol for MR imaging of lymphatic vessels in lymphoedematous patients: initial experience after intracutaneous injection

C Lohrmann, MD1, E Foeldi, MD2, J-P Bartholomae, MD1 and M Langer, MD1

1 Division of Diagnostic Radiology, Department of Radiology, University Hospital of Freiburg, Hugstetter Strasse 55, D-79106, Freiburg, 2 Foeldi Clinic for Lymphology, Hinterzarten, Rößlehofweg 2–6, D-79856, Hinterzarten, Germany

Correspondence: Christian Lohrmann MD, Universitätsklinikum Freiburg, Abteilung Röntgendiagnostik, Hugstetter Strasse 55, 79106 Freiburg i. Br., Germany. E-mail: lohrmann{at}mrs1.ukl.uni-freiburg.de

The aim of this study was to evaluate the feasibility of gadoteridol in visualizing lymphatic vessels of lymphoedematous patients after intracutaneous injection. 20 lower extremities in 10 lymphoedematous patients were examined. Gadoteridol (9 ml) was subdivided into five portions and injected intracutaneously into the dorsal aspect of each foot. For MRI, a three-dimensional spoiled gradient echo sequence was performed. No complications were observed during or after intracutaneous injection of gadoteridol. The lymphoedema was bilateral in seven and unilateral in three of the examined patients. Contrast enhancement of gadoteridol was detected in lymphatic vessels at the level of the lower leg in 17 lower extremities (85%). Enhancing lymphatic vessels of the upper leg were observed in 11 lower extremities (55%). Furthermore, gadoteridol enhanced 10 out of 20 inguinal lymph node groups (50%). No external iliac lymph nodes were observed in any of the patients. Regions of dermal backflow, indicating proximal lymphatic obstruction, were seen in 13 lower extremities (65%). As soon as 15 min after gadoteridol injection, accompanying venous enhancement was detected in all lower extremities (100%). MRI of lymphatic vessels in lymphoedematous patients is safe and feasible after intracutaneous injection of gadoteridol if the diagnosis of lymphoedema necessitates a better definition for optimal therapeutic planning or an objective, diagnostic baseline is required. The proposed technique represents a minimally invasive imaging method of identifying anatomical and physiological derangements in lymphatic vessels.




This article has been cited by other articles:


Home page
J Am Coll CardiolHome page
S. G. Rockson
Diagnosis and Management of Lymphatic Vascular Disease
J. Am. Coll. Cardiol., September 2, 2008; 52(10): 799 - 806.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
BJR DMFR IMAGING  ALL BIR JOURNALS 
Copyright © 2007 by the British Institute of Radiology.